A protein called CD73 may differ between grade 1 and grade 2 meningiomas
Original title: CD73 and PD-L1 expression in WHO grade 1 and grade 2 meningiomas: an exploratory analysis of purinergic and immune-related profiles.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This looked at tumors from people, but it is an early study and not a treatment.
The short version
Researchers found early signs that one protein is higher in grade 2 meningiomas, but this is only a first look.
What was studied. Forty people who had surgery to remove a meningioma took part. Researchers looked at their tumors and blood for certain proteins linked to the immune system.
What they found. A protein called CD73 was higher in grade 2 tumors than in grade 1 tumors. Another protein, called PD-L1, was lower in grade 2 tumors. Some signs of swelling in the blood were a bit higher with grade 2 tumors, but not by a clear amount.
What this means, and what it doesn't
What it could mean: CD73 might one day help doctors tell tumor grades apart. It could also point researchers toward new ideas to study.
What it doesn't mean: This does not mean CD73 causes tumors to grow or get worse. The study was small and looked at people only once, not over time. It is not a test or treatment you can get now. It is not a cure. Larger studies are needed to check these results.
Source: PubMed, September 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.